Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data

BMC Cancer

Research Article

Rentao Yu¹  Zhaoxia Tan¹  Yunjie Dan¹  Xiaomei Xiang¹  Guohong Deng² 

[1] Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, 400038, Chongqing, China;Chongqing Key Laboratory of Infectious Diseases, Southwest Hospital, Third Military Medical University, 400038, Chongqing, China;Department of Infectious Diseases, Southwest Hospital, Third Military Medical University, 400038, Chongqing, China;Chongqing Key Laboratory of Infectious Diseases, Southwest Hospital, Third Military Medical University, 400038, Chongqing, China;Institute of Immunology, Third Military Medical University, 400038, Chongqing, China;

关键词: PIVKA-II;    HCC;    Real-world;    AFP;    Surveillance;   

DOI  :  10.1186/s12885-017-3609-6

 received in 2017-06-13, accepted in 2017-08-24,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundProtein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) is an efficient biomarker specific for hepatocellular carcinoma (HCC). Some researchers have proved that levels of PIVKA-II reflect HCC oncogenesis and progression. However, the effectiveness of PIVKA-II based on real-world clnical data has barely been studied.MethodsA total of 14,861 samples were tested in Southwest Hospital in over 2 years’ time. Among them, 4073 samples were PIVKA-II positive. Finally, a total of 2070 patients with at least two image examinations were enrolled in this study. Levels of AFP and PIVKA-II were measured by chemiluminescence enzyme immunoassay (CLEIA) and chemiluminescent microparticle Immunoassay (CMIA), respectively.ResultsA total of 1016 patients with HCC were detected by PIVKA-II in a real-world application. In all these cases, 88.7% cases primarily occurred and patients with advanced HCC covered 61.3%. Levels of PIVKA-II were significantly higher in advanced group (4650.0 mAU/ml, 667.0–33,438.0 mAU/ml) than early-stage group (104.5 mAU/ml, 61.0–348.8 mAU/ml; P < 0.001). Levels of PIVKA-II elevated significantly in recurrence and residual group than recovery group (P < 0.001). A total of 1054 PIVKA-II positive patients were non-HCC cases. Among them, cirrhosis took the largest part (46.3%), followed by hepatitis (20.6%) and benign nodules (15.3%). High-levels of PIVKA-II in at-risk patients is an indicator of HCC development in two-year time.ConclusionsOur data showed that PIVKA-II effectively increases the detection rate of HCC was a valid complement to AFP and image examination in HCC surveillance.

【 授权许可】

CC BY   
© The Author(s). 2017